Sequoia-backed in-vitro diagnosis focused biomedicine company Shenzhen New Industries Biomedical Engineering Co., Ltd (also known as Snibe) has kicked off its IPO subscription exercise targeting to raise 1.29 billion yuan ($183 million) on the ChiNext board of the Shenzhen Stock Exchange.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
